BridgeBio
在场
高管
查看带有其 45 名主要高管的组织结构图
BridgeBio 搜索最多的简介
高管在BridgeBio变化
- Thomas Trimarchi 曾任 Chief Product Officer, 现升职为 President and Chief Operating Officer (新闻发布的2024七月24号).
创建提醒
跟踪 BridgeBio 的高管变动
生物技术
BridgeBio 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
BridgeBio 的最新新闻稿
- BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - BridgeBio
- BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management - BridgeBio
- BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - BridgeBio
- BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio
- BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events - BridgeBio
- BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) - BridgeBio
- BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA - BridgeBio
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - BridgeBio
- News | BridgeBio
- BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program - BridgeBio
- View more press releases Close
通过电子邮件
